| 000 | 01837 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250514023619.0 | ||
| 264 | 0 | _c20020222 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/hc0602.104675 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTakeda, Yoshiyu | |
| 245 | 0 | 0 |
_aCalcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. _h[electronic resource] |
| 260 |
_bCirculation _cFeb 2002 |
||
| 300 |
_a677-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAldosterone |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xpharmacology |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xpharmacology |
| 650 | 0 | 4 |
_aAtrial Natriuretic Factor _xgenetics |
| 650 | 0 | 4 | _aBody Weight |
| 650 | 0 | 4 |
_aCalcineurin _xmetabolism |
| 650 | 0 | 4 | _aCalcineurin Inhibitors |
| 650 | 0 | 4 |
_aCardiomegaly _xchemically induced |
| 650 | 0 | 4 |
_aCollagen Type III _xmetabolism |
| 650 | 0 | 4 |
_aCyclosporine _xpharmacology |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aFibrosis _xchemically induced |
| 650 | 0 | 4 |
_aHeart _xdrug effects |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xpharmacology |
| 650 | 0 | 4 |
_aLosartan _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMineralocorticoids |
| 650 | 0 | 4 |
_aMyocardium _xmetabolism |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 |
_aOrgan Size _xdrug effects |
| 650 | 0 | 4 |
_aRNA, Messenger _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Inbred WKY |
| 650 | 0 | 4 | _aSodium Chloride, Dietary |
| 650 | 0 | 4 |
_aTacrolimus _xpharmacology |
| 700 | 1 | _aYoneda, Takashi | |
| 700 | 1 | _aDemura, Masashi | |
| 700 | 1 | _aUsukura, Mikiya | |
| 700 | 1 | _aMabuchi, Hiroshi | |
| 773 | 0 |
_tCirculation _gvol. 105 _gno. 6 _gp. 677-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/hc0602.104675 _zAvailable from publisher's website |
| 999 |
_c11748556 _d11748556 |
||